Tscan Therapeutics Inc’s recently made public that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $1.67 million on May 19 ’25. In the deal valued at $1.20 per share,1,388,794 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 6,746,141 shares worth roughly $10.39 million.
Then, Lynx1 Capital Management LP bought 1,200,000 shares, generating $1,440,000 in total proceeds. Upon buying the shares at $1.20, the 10% Owner now owns 7,946,141 shares.
Before that, Lynx1 Capital Management LP bought 100,000 shares. Tscan Therapeutics Inc shares valued at $290,140 were divested by the 10% Owner at a price of $2.90 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 5,357,347 shares, worth roughly $8.25 million.
BTIG Research initiated its Tscan Therapeutics Inc [TCRX] rating to a Buy in a research note published on May 16, 2024; the price target was $12. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Wedbush began covering TCRX with “an Outperform” recommendation on June 22, 2023.
Price Performance Review of TCRX
On Tuesday, Tscan Therapeutics Inc [NASDAQ:TCRX] saw its stock jump 0.65% to $1.54. Over the last five days, the stock has lost -8.88%. Tscan Therapeutics Inc shares have fallen nearly -49.34% since the year began. Nevertheless, the stocks have fallen -82.89% over the past one year. While a 52-week high of $8.51 was reached on 01/03/25, a 52-week low of $1.02 was recorded on 04/09/25.
Levels Of Support And Resistance For TCRX Stock
The 24-hour chart illustrates a support level at 1.4567, which if violated will result in even more drops to 1.3733. On the upside, there is a resistance level at 1.6167. A further resistance level may holdings at 1.6933.
